Shire plasma center gets first FDA approval

Ireland-incorporated rare diseases giant Shire (LSE: SHP) announced on Friday that it had receieved approval from the US Food and Drug Administration (FDA) on its first submission for a new plasma manufacturing center in the state of Georgia.

The facility, which has received approval for the manufacture of Gammagard (immunoglobulin 10%), would add 30% to the company's plasma production capacity when completed. The value of Shire's plasma portfolio has increased 18% in 2017 and a further 12% in Q1 of 2018.

"The site will support Shire’s growing immunology franchise"